MAP BioPharma works closely with several organisations that share our commitment and vision to accelerate patient access and provide innovative solutions to BioPharma and MedTech companies. If you would like an introduction to any of these organisations get in touch by emailing email@example.com .
Pharos is a highly specialised consulting network of 5 renowned agencies with experience in delivering a winning launch across Europe at a fair price. MAP BioPharma is one of those partners and together the network provides extensive expertise in supporting companies for market access, pricing, and reimbursement activities across Europe. This network provides unique and confidential access to decision makers and unprecedented expertise in local healthcare markets in Europe.
The aim of N-Site is simple: to be the primary hub of expert guidance for UK based Life Science companies – from embryonic start-ups to established multinationals.
N-Site contains key documents, guidance and legislative developments of relevance to your Life Science business, ensuring that you have the right information to help you make critical strategic decisions. In terms of relevance and insight, the guidance offered here extends far beyond that which is currently freely available.
EUCOPE is Europe’s trade body for small to medium-sized innovative companies working in the field of pharmaceuticals and medical technologies.
Based in Brussels, Belgium, EUCOPE gives voice to more than 900 research-oriented innovative companies and associations active in research, development of pharmaceuticals, biotechnologies and medical devices. Many of our members are developing therapeutic solutions for persons living with a rare disease, who had little to no treatment available just a few years ago.
EMIG has over 300 Member Companies and organisations – including Associate Members drawn from academia, patient organisations, learned societies and companies providing essential support services to the Life Sciences ecosystem. Collectively we represent the breadth of the health and medicines ecosystem, from research, clinical development, and manufacturing, through to patient charities, research policy organisations and academic institutions. This means EMIG has become a platform for greater knowledge and ideas exchange.
At $2.8 trillion dollars, the United States is the largest healthcare market in the world. With extensive knowledge of the Life Sciences and the US market, BioPortUSA address your unique needs and provide a customized plan and suite of services, making the entire process seamless. They can provide help with:
• Obtaining FDA Approval
• Assist with reimbursement
• Identify strategic partners
Pharma14 is a leading global medicine database platform used by a wide spectrum of life science companies. Their monthly updated platform is used by governmental agencies, pharmaceutical companies, consultants, CMOs, API manufacturers, wholesalers, and pharmacy retail chains. Pharma14’s robust and accurate medicine data, as well as its industry leading drug pricing and reimbursement information give its members the tools required to compete in todays’ market. Key pricing drivers such as generics, parallel trade, biosimilars, niche markets and more provide unique industry insights.
Copyright © 2020. MAP BioPharma Limited. All rights reserved.
MAP BioPharma Limited
Upper Pendrill Court, Ermine Street North
Papworth Everard, Cambridge
Cambridgeshire, CB23 3UY
+44 (0) 1480 832360
MAP BioPharma Limited is a registered company in England and Wales. Company Registration Number 08209281
VAT Group Registration Number GB 292 8576 52